We are bringing together the acute care community to learn from industry experts and share best practices. Through education we can all strive to provide optimal patient care.
Your peer to peer based clinical education resource for acute care.
Learn from shared experience of world-renowned leaders on Acute Care topics including AKI, renal therapies, CRRT and Therapeutic Plasma Exchange.
Stay on top of the latest in renal care with online learning delivered live and on-demand for your convenience.
Gather insights and best practices at local round tables of industry experts.
Overcoming Challenges of Medication Dosing in Continuous Renal Replacement Therapy
Location: Online via Baxter Webcast
Date: Wednesday October 23, 2019
Incidence of Acute Kidney Injury
of hospitalized patients worldwide are estimated to have Acute Kidney Injury.3
of adult ICU patients are estimated to have Acute Kidney Injury and 20% of them receiving dialysis.14
of children and young adults admitted to an ICU develop Acute Kidney Injury.14
AKI is connected to the use of nephrotoxic drugs in 20-30% of patients.
Acute Kidney Injury is a subset of Acute Kidney Disease
Both AKI and AKD without AKI can be part of chronic kidney disease (CKD).1 CKD is determined to exist if a kidney experiences damage for over three months, while AKI does not have this set threshold.1 AKI is neither only acute tubular necrosis (ATN) nor renal failure.1 Instead it is a syndrome that spans these states as well as those less severe.1 Renal failure is just one potential stage of AKI.1 AKI Stage 3 is defined as 3 times baseline of SCr or increase in SCr to ≥4.0 mg/dl and/or decrease in eGFR to <35 ml/min per 1.73 m2 in patients <18 years.1 That level is considered a threshold for RRT, even though RRT could be required earlier in the evolution of AKI.1